Apixaban is a novel oral anticoagulant (NOAC) approved by the US Food and Drug Administration (FDA) in 2012.

**FDA-approved Indications**

- It is indicated in patients with non-valvular atrial fibrillation to reduce the risk of stroke and systemic embolism.

- It is also approved for the treatment of deep vein thrombosis (DVT).

- It is approved for the treatment of pulmonary embolism (PE).

- It is also indicated for the prophylaxis in DVT, which may lead to PE, in patients who may have undergone knee or hip replacement surgery.

- It is also approved for reducing the risk of recurrent DVT and PE after initial therapy.